Biolevate, a Paris-based startup, has raised €6 million in seed funding led by EQT Ventures, with participation from bpifrance and several angel investors. The company aims to address a pressing challenge in healthcare—streamlining medical writing with artificial intelligence. This funding milestone will support Biolevate’s efforts to refine its proprietary AI platform, ELISE, and expand its team with top talent.
The raised money will primarily fund product enhancement and team expansion. Biolevate also plans to capitalise on its recent inclusion in Station F’s Future 40 list by strengthening its presence in the healthcare tech landscape. With EQT Ventures backing its vision, the company is well-positioned to scale its impact globally.
Just a while back, we also reported about how Fresho secured $17M to empower fresh food wholesale with AI-enabled ordering. It’s an interesting startup as well.
Medical writing, a critical component in bringing healthcare products to market, is time-consuming and resource-intensive. It involves creating and maintaining thousands of pages of documentation across the lifecycle of medical products, from preclinical studies to post-market surveillance.
Joël Belafa, Biolevate’s CEO, stated, “Artificial intelligence has immense potential, and we established Biolevate with a clear mission of using AI to accelerate the development of new therapies, ensuring patients receive life-saving treatments faster.”
What problem is the startup trying to solve
The medical writing profession, essential for meeting stringent regulatory standards, is facing workforce shortages globally. Over the past decade, pharmaceutical R&D spending has doubled, further straining the capacity for documentation. Biolevate’s ELISE platform steps in to fill this gap by automating the creation, validation, and management of regulatory documents.
Biolevate’s ELISE leverages advanced technologies like Natural Language Processing (NLP), Graph Neural Networks (GNN), and Computer Vision to assist in real-time collaborative medical writing. The platform provides instant suggestions, compliance checks, and automated literature reviews, making it a valuable tool for researchers, regulatory professionals, and market access experts.
By reducing manual effort, ELISE not only saves time but also enhances document accuracy and consistency, paving the way for faster drug approvals.
Beyond writing, ELISE supports complex data analysis, risk assessments, and anomaly detection, adding another layer of efficiency to medical R&D. Julien Hobeika, Partner at EQT Ventures, highlighted the platform’s long-term potential, saying, “In the long run, their platform can augment any scientist, working with any type of materials.”
Is there any market opportunity
The healthcare sector’s growing reliance on AI is evident, with companies racing to integrate intelligent solutions into workflows. Statista reports global pharmaceutical R&D spending has doubled in the last decade, underscoring the need for technologies that expedite processes while ensuring regulatory compliance. Biolevate’s approach is particularly relevant in this context, offering tools tailored to pharmaceutical, cosmetic, and medical device industries.
Biolevate’s mission goes beyond efficiency. By reducing the time and cost associated with medical writing, the platform helps accelerate the availability of therapies to patients. With its transparent and collaborative design, ELISE fosters better communication among stakeholders, ensuring the integration of the latest research and compliance standards.
Challenges and ethical considerations
While AI’s role in healthcare innovation is promising, it also raises questions about transparency, data security, and workforce implications. Automating processes like medical writing could lead to concerns about job displacement and dependency on algorithms for critical documentation. Biolevate’s approach, focusing on complementing human expertise, rather than replacing it, offers a balanced path forward.
What do we think about the startup
Biolevate’s AI-driven platform marks a significant step toward modernising healthcare workflows. By addressing longstanding inefficiencies in medical writing, the company is positioned to play a pivotal role in accelerating the development and accessibility of life-saving therapies.
As the healthcare sector continues to embrace AI, Biolevate’s success will likely set a precedent for other startups aiming to navigate the complex intersection of technology and medicine.
The post How Paris-based Biolevate is streamlining medical writing with AI: Strikes €6M seed round appeared first on Tech Funding News.